WO2000001392B1 - 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (et180ch3) for the treatment of human carcinoma of the breast - Google Patents
1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (et180ch3) for the treatment of human carcinoma of the breastInfo
- Publication number
- WO2000001392B1 WO2000001392B1 PCT/EP1999/004563 EP9904563W WO0001392B1 WO 2000001392 B1 WO2000001392 B1 WO 2000001392B1 EP 9904563 W EP9904563 W EP 9904563W WO 0001392 B1 WO0001392 B1 WO 0001392B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- 8och3
- breast
- et18och3
- et180ch3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (ET180CH3) for the treatment of human carcinomas of the breast and to the preparation of a medicament for the treatment of human carcinomas of the breast. The active ingredient used is ET180CH3, which has been transferred into a form suitable for oral administration in a liquid excipient.
Claims
1. Verfahren zur Herstellung eines für die orale Verabreichung bestimmten Arzneimittels zur Behandlung von humanen Mammakarzinomen durch Reinduktion von deren Apoptose, d a d u rc h g e k e n n z e i c h n et , dass als Wirkstoff ET18OCH3 verwendet wird, das in einem flüssigen Trägermittel auf Wasserbasis mit mindestens 3 % Fett und/oder Proteingehalt gelöst wird.1. A process for the preparation of a medicament intended for oral administration for the treatment of human breast carcinomas by re-induction of their apoptosis, dadu rc hgekennzeichn et that ET18OCH3 is used as the active ingredient, which is in a liquid water-based vehicle with at least 3% fat and / or Protein content is solved.
2. Verfahren nach Anspruch 1, d a d u rc h g e k e n n ze i c h n et , dass das Trägermittel Milch umfasst.2. The method of claim 1, d a d u rc h g e k e n n ze i c h n et that the carrier comprises milk.
3. Verfahren zur Behandlung von Mammakarzinomen, d a d u rc h g e k e n n ze i c h n et , dass man einer behandlungsbedürftigen Person eine pharmakologisch wirksame Menge an ET18OCH3 in einem flüssigen trinkbaren Trägermaterial, das mindestens 3 Gew.-% Fett und/oder Protein enthält, oral verabreicht.3. A method for the treatment of breast carcinomas, ie that a pharmacologically effective amount of ET18OCH3 is orally administered to a person in need of treatment in a liquid drinkable carrier material which contains at least 3% by weight of fat and / or protein.
4. Verfahren nach Anspruch 3, d a d u rc h g e k e n n ze i c h n et , dass man als Trägermaterial Milch verwendet.4. The method of claim 3, d a d u rc h g e k e n n ze i c h n et that milk is used as the carrier material.
5. Verfahren nach Anspruch 3 oder 4, d a d u rc h g e k e n n z e i c h n et ,
2 75. The method according to claim 3 or 4, dadu rc hgekennzeichn et, 2 7
dass man den Wirkstoff in einer Menge von 50 bis 900 mg/Tag/Person verabreicht.
that the active ingredient is administered in an amount of 50 to 900 mg / day / person.
2828
IN ARTIKEL 19 GENANNTE ERKLÄRUNGDECLARATION REFERRED TO IN ARTICLE 19
Zu den im Recherchenbericht zitierten Literaturstellen ist in Bezug auf die neuen Ansprüche folgendes zu bemerken:Regarding the literature references cited in the search report, the following should be noted in relation to the new claims:
1 . DE 40 00 084 offenbart die intravenöse Verabreichung von ET18OCH3 in einer niedrigen zytostatischen Dosierung. Die orale Behandlung eines Mammakarzinoms wird nicht offenbart.1 . DE 40 00 084 discloses the intravenous administration of ET18OCH3 in a low cytostatic dosage. Oral treatment for breast cancer is not disclosed.
2. DE 41 32 345, WO 98/1 6200 A und US 5,762,958 betreffen liposomale Formulierungen von ET1 8OCH3. Es ist bekannt, dass freies ET1 8OCH3 sehr viel toxischer ist als liposomal gebundenes.2. DE 41 32 345, WO 98/1 6200 A and US 5,762,958 relate to liposomal formulations of ET1 8OCH3. Free ET1 8OCH3 is known to be much more toxic than liposomally bound.
3. WO 87/04765 lehrt die Verwendung eines CoA-IT Inhibitors unter anderem auch in Kombination mit ET1 8OCH3 bei Psoriasis, rheumatoider Arthritits, Arteriosklerose oder Krebs.3. WO 87/04765 teaches the use of a CoA-IT inhibitor inter alia also in combination with ET1 8OCH3 in psoriasis, rheumatoid arthritis, arteriosclerosis or cancer.
4. DE 39 41 009 betrifft die Eliminierung von aktivierten Lymphozyten mittels ET1 8OCH3.4. DE 39 41 009 relates to the elimination of activated lymphocytes using ET1 8OCH3.
5. Der Artikel von Hartmann et al., Simon et al., und Kosano et al. betreffen spezielle Untersuchungen über Mehrkomponentensysteme, die nur in vitro (Simon, Kosano) oder am Tier durchgeführt wurden. In keinem Falle finden sich Hinweise auf die erfindungsgemäße Formulierung.
5. The article by Hartmann et al., Simon et al., And Kosano et al. concern special studies on multi-component systems that were only carried out in vitro (Simon, Kosano) or on animals. In no case are there indications of the formulation according to the invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99932780A EP1091744A1 (en) | 1998-07-01 | 1999-07-01 | 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (et180ch3) for the treatment of human carcinoma of the breast |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1998129448 DE19829448A1 (en) | 1998-07-01 | 1998-07-01 | 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholine (ET180CH3) for the treatment of human breast cancer |
| DE19829448.4 | 1998-07-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2000001392A1 WO2000001392A1 (en) | 2000-01-13 |
| WO2000001392B1 true WO2000001392B1 (en) | 2000-02-24 |
Family
ID=7872671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1999/004563 WO2000001392A1 (en) | 1998-07-01 | 1999-07-01 | 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (et180ch3) for the treatment of human carcinoma of the breast |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1091744A1 (en) |
| DE (1) | DE19829448A1 (en) |
| WO (1) | WO2000001392A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1135193E (en) * | 1998-12-04 | 2003-01-31 | Max Delbrueck Centrum | AGENTS FOR THE TREATMENT OF TUMORS BASED ON LIPOSOMES AND COMPREHENDING TAMOXYPHEN |
| US7041302B2 (en) * | 2001-01-09 | 2006-05-09 | Biother Corporation | Therapeutic modulation of the tumor inflammatory response |
| DE102006019907A1 (en) * | 2006-04-28 | 2007-10-31 | Müller-Enoch, Dieter, Prof. Dr. | Use of substituted glycerin derivative in the preparation of a pharmaceutical composition for the prevention or treatment of e.g. cancer disease, pathological sequence of alcohol abuse, viral hepatitis and toxic nerve disorder |
| RU2009121838A (en) | 2006-11-10 | 2010-12-20 | Альфаптозе ГмбХ (DE) | ORAL DOSAGE FORM CONTAINING COMPOUNDS OF TRIZOMISED GLYCERINE |
| EP2120873B1 (en) * | 2006-12-20 | 2012-06-27 | Alphaptose Gmbh | Topical dosage form comprising tri-substituted glycerol compounds |
| RU2474427C2 (en) | 2006-12-20 | 2013-02-10 | Универзитетсклиникум Хамбург-Эппендорф | Use of tri-substituted glycerol compounds for treating hematological malignant tumours |
| WO2013156630A1 (en) | 2012-04-20 | 2013-10-24 | Alphaptose Gmbh | S-enantiomer of a tri-substituted glycerol compound |
| GB201208850D0 (en) * | 2012-05-18 | 2012-07-04 | Alphaptose Gmbh | Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3941009A1 (en) * | 1989-12-12 | 1991-06-13 | Medmark Pharma Gmbh | ELIMINATION OF ACTIVATED LYMPHOCYTES |
| DE4000084A1 (en) * | 1990-01-03 | 1991-07-04 | Medmark Pharma Gmbh | INTRAVENOES APPLICABLE PHARMACEUTICAL PREPARATION OF ET18-OCH (DOWN ARROW) 3 (DOWN ARROW) |
| DE4132345A1 (en) * | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | Medicament compsns. for intravenous admin. of lytic agents - used for treatment of tumours, auto-immune disorders, multiple sclerosis, etc. |
| PT785773E (en) * | 1994-10-14 | 2001-05-31 | Liposome Co Inc | LIPOSOMES OF LIPIDIC ETERES AND THEIR THERAPEUTIC UTILIZATION |
| WO1997004765A1 (en) * | 1995-07-25 | 1997-02-13 | Smithkline Beecham Corporation | INHIBITION OF CoA-INDEPENDENT TRANSACYLASE AND APOPTOSIS |
| US5932242A (en) * | 1996-10-15 | 1999-08-03 | The Liposome Company, Inc. | Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof |
-
1998
- 1998-07-01 DE DE1998129448 patent/DE19829448A1/en not_active Withdrawn
-
1999
- 1999-07-01 WO PCT/EP1999/004563 patent/WO2000001392A1/en not_active Application Discontinuation
- 1999-07-01 EP EP99932780A patent/EP1091744A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1091744A1 (en) | 2001-04-18 |
| WO2000001392A1 (en) | 2000-01-13 |
| DE19829448A1 (en) | 2000-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60202278T2 (en) | ACTIVATION OF NATURAL KILLER CELLS BY ADENOSINE A3 RECEPTOR AGONISTS | |
| DE1492015A1 (en) | Improved form of administration of pharmaceutical preparations | |
| DE60012230T2 (en) | USE OF OLIGOSACCHARIDE-CONTAINING DERMATOLOGIC PREPARATION FOR THE TREATMENT OF SKIN DISEASES | |
| DE3438470A1 (en) | AGENT FOR PROPHYLACTIC TREATMENT OF OSTEITIS AND OSTEOMYELITIS | |
| DE3430799A1 (en) | METHOD FOR TREATING OSTEOPOROSIS | |
| WO2000019999A1 (en) | Fulvic acid and its use in the treatment of various conditions | |
| DE2947742A1 (en) | (BETA) -CYCLODEXTRIN AS AN ANTI-ACNE AGENT | |
| AU5988086A (en) | New carboxylic acid derivatives, processes for the preparation thereof, the use thereof and pharmaceutical compositions containing them | |
| EP0236951A2 (en) | Use of diphenyl hydantoin and its derivatives in the preparation of a pharmaceutical agent for the treatment of immune diseases | |
| WO2000001392B1 (en) | 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (et180ch3) for the treatment of human carcinoma of the breast | |
| EP0185210A2 (en) | Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis | |
| CH683824A5 (en) | Composition as an agent for treatment of inflammation. | |
| DE69819012T2 (en) | PHARMACEUTICAL COMPOSITION FOR REDUCING MCP-1 PROTEIN SYNTHESIS | |
| EP0369216B1 (en) | Pharmaceutical preparation based on ester derivatives of hecogenine, and their use in treating benign prostatic hyperplasia | |
| EP0236390A1 (en) | Agent against multiple sclerosis. | |
| EP2047855B1 (en) | Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants) | |
| DE2729824A1 (en) | PHARMACEUTICAL COMPOSITIONS WITH ORGANIC MONTMORILLONITE DERIVATIVES AND THEIR PRODUCTION | |
| DE2206570C3 (en) | Use of (+) - catechin | |
| JPH069391A (en) | Hyaluronidase activity inhibitor | |
| DE69630974T2 (en) | HYALURONIC ACID RECEPTORS AND THEIR USE FOR TREATMENT OF TUMORS AND RESTENOSIS | |
| DE60128801T2 (en) | Isoflavones against radiation-induced mortality | |
| EP0817623B1 (en) | Medicaments for the selective treatment of tumour tissues | |
| DE3311922A1 (en) | ANTIFIBROTIC AGENTS | |
| DE2451933C2 (en) | ||
| DE19650778A1 (en) | Dopamine receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: B1 Designated state(s): CN JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1999932780 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999932780 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1999932780 Country of ref document: EP |